Skip to content

Safety of Tranexamic Acid in Reducing Blood Loss Myomectomy.

Safety of Tranexamic Acid Versus Misoprostol in Reducing Blood Loss in Myomectomy.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04694677
Enrollment
60
Registered
2021-01-05
Start date
2021-01-10
Completion date
2021-09-10
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myoma

Brief summary

Uterine leiomyomas (fibroids) are the most common benign tumors among women . Fibroids are found in approximately 15% to 30% of women in the reproductive age group

Detailed description

Although most of them are asymptomatic, 20-50% of fibroids may cause problems such as heavy menstrual bleeding, anemia, pelvic pain, pressure symptoms from extrinsic compression of the colorectal and urinary tract, infertility, and recurrent pregnancy losses, where surgical intervention is often indicated

Interventions

DRUGwomen receiving tranexamic acid

women receiving tranexamic acid during myomectomy

DRUGwomen receiving misoprostol

women receiving misoprostol in myomectomy

Sponsors

Cairo University
CollaboratorOTHER
Aljazeera Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* women with myomas

Exclusion criteria

* with with malignant lesions

Design outcomes

Primary

MeasureTime frameDescription
the number of women who will have less blood loss48 hourshow many women will have less blood loss

Countries

Egypt

Contacts

Primary ContactMahmoud Alalfy
mahmoudalalfy@ymail.com01002611058

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026